Daily Archives: May 2, 2018

Talenthon, a UK Based Start-up Selected as the Best ICO to Invest in for 2018

LONDON, May 2, 2018 /PRNewswire/ —
There are thousands of Initial Coin Offerings (ICOs) on the market today but only a few would get the public trust. According to CoinTelegraph, Talenthon, a UK based Recruitment Platform, is the best ICO project for 2018 and is undoubtedly the…

PR NEWSWIRE

BitUN and IPP Financial Services Holdings Limited Announce Strategic Cooperation

SINGAPORE, May 2, 2018 /PRNewswire/ — On 2 May 2018, Blockchain asset private bank BitUN and IPP Financial Services Holdings Limited (IPP) announced a strategic collaboration to promote the development of Blockchain technologies in the financial planning arena. BitUN and IPP will leverage…

PR NEWSWIRE

GEX Management And LL Roberts Group To Open Joint Sales & Service Center In Northwest Arkansas

DALLAS, May 2, 2018 /PRNewswire/ — GEX Management, Inc. (OTCQB: GXXM), announced that it has reached agreement in principle with LL Roberts Group, a Dallas, Texas-based Professional Employer Organization (PEO), to jointly open and operate a PEO Sales & Service Center in Northwest…

PR NEWSWIRE

Blockchain + AI, Sophon Capital Community Redefines Black-Tech in Digital Asset Services

Dr. Bai Shuo (Right) and Dr. Frank Zheng, the witnesses of Signing Ceremony of the Agreement for Strategic CooperationsSHANGHAI, May 2, 2018 /PRNewswire/ — Sophon Capital Community-a digital asset service community based on blockchain and AI technology-provides users with 24/7 real time, valuable, efficient and multi-lingual digital currency intelligent investment services, information services, and…

PR NEWSWIRE

Mavenclad (Cladribine Tablets) Data in Multiple Sclerosis Journal Show an Even Greater Treatment Effect in Patients With Highly Active Multiple Sclerosis

Merck LogoDARMSTADT, Germany, May 2, 2018 /PRNewswire/ — Merck, a leading science and technology company, today announced the Multiple Sclerosis Journal publication of data outlining the effects of MAVENCLAD® (cladribine tablets) treatment on two subgroups of patients with highly active relapsing…

PR NEWSWIRE